Sixteen studies (n unknown) were included in the review (one RCT; seven before-and-after studies; eight case series or audits with no comparator group). Only studies with a comparator group were included in the analysis .
Survival (one RCT, four before-and-after studies)
One study reported an improvement in median survival of 3.2 months (p<0.001) for the multidisciplinary group compared to the control group. Another other study reported an increase in the number of lung cancer patients older than 70 years surviving at one year (increase from 18.4 per cent to 23.5 per cent, p=0.049) for those receiving care from the multidisciplinary team. Three other studies, including one RCT, found no statistically significant differences between groups.
A greater percentage of participants in the multidisciplinary group received radical treatment such as chemotherapy, radiotherapy or resection compared to those in the control arm (six studies). This difference reached statistical significance in the before-and-after studies, but not in the RCT. Higher rates of resection were reported in multidisciplinary groups in three other studies (three before-and-after studies). Two studies (one RCT, one before-and-after study) reported reductions in median time from presentation to first treatment for multidisciplinary groups. One before-and-after study found no statistically significant differences between groups for waiting times. Significantly fewer visits to a general practitioner were reported for the multidisciplinary group compared to the control group (p<0.02, one RCT). There were no statistically significant differences between groups in terms of quality of life (one RCT)